Technology Holdings advises ServiceNow Elite Partner Unifii on its strategic sale to Bain Capital backed Inetum
Technology Holdings, a global investment bank with offices in North America, Europe and the Asia-Pacific is pleased to announce that it has acted as the exclusive financial advisor to London headquartered Elite ServiceNow partner, Unifii on its strategic sale to Bain Capital backed Inetum, which is headquartered in France.
Unifii is the largest independent Elite ServiceNow partner in the United Kingdom and Ireland, and is recognized for its unparalleled expertise in supporting clients through their digital transformation journeys. Unifii enables its clients to achieve successful business outcomes through optimized business workflows. Unifii has a recognized customer ecosystem in multiple sectors, including finance, technology, and the public sector. Its team of certified experts and experienced consultants brings undeniable value to its clients’ national and international projects.
With the acquisition of Unifii, Inetum becomes a leading European partner for ServiceNow with nearly 500 ServiceNow experts in Europe and more than 2000 certifications. Inetum offers a full set of services and business transformation solutions on the ServiceNow platform with operational skills covering a wide geographic scope on ServiceNow from the United Kingdom and Ireland to Eastern Europe, Spain, Portugal, France, Belgium, Switzerland, and Luxembourg. This strategic European footprint positions Inetum as a key player in Europe, offering offshore capabilities in India.
“Technology Holdings’ dedication, track record and deep understanding of the ServiceNow and Digital Transformation market, combined with their depth of knowledge of the key strategic and Private Equity players globally ensured that we were able to optimally navigate this deal process and maximize value for our business and employees. As a result, we are very excited to embark on our new partnership with Inetum, where we see tremendous strategic and cultural synergies.” said Stephen Mamelok, Managing Director of Unifii.
Vivek Subramanyam, Founder and CEO of Technology Holdings said, “We are elated to have closed this key transaction in the ServiceNow ecosystem for Elite Partner, Unifii – our 7th ServiceNow transaction. This transaction is yet another testament to Technology Holdings’ deep expertise and positions us as the ServiceNow and Digital Transformation investment bank of choice globally. It was a real pleasure to have worked with Steve and Mike at Unifii, and we wish them tremendous success in their partnership with Inetum.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Marketing Manager
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Announces Grant of Employment Inducement Awards1.3.2024 22:15:00 CET | Press release
IFF (NYSE: IFF) today announced the grant of employment inducement awards to J. Erik Fyrwald, IFF Chief Executive Officer and member of the Board of Directors. The Company's Board of Directors approved the employment inducement awards on Jan. 9, 2024, with a grant date of March 1, 2024, as a material inducement to enter into an offer of employment in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08 that requires shareholder approval of equity-based compensation plans. Listing Rule 303A.08 requires the public announcement of such an award. The inducement awards will consist of (i) a target award of 68,750 performance share units (with a maximum award of 171,875 performance share units), subject to meeting the applicable performance targets set forth in the award agreement, and (ii) 56,250 restricted stock units, 100% of which will vest on the three-year anniversary of the grant date, for a maximum potential combined payout of 228,125
Whitehorse Liquidity Partners Recognized by Private Equity International’s 2023 Awards1.3.2024 16:30:00 CET | Press release
Whitehorse Liquidity Partners (together with its advisory affiliates, “Whitehorse”), a specialized investment manager focused on providing structured liquidity solutions to the alternative asset class, is pleased to announce recognition from Private Equity International (PEI) in the 2023 PEI Awards. Whitehorse placed third in the Secondaries Firm of the Year in the Americas category alongside Blackstone Strategic Partners and HarbourVest Partners and was voted Firm of the Year in Canada. “We are honoured to have been recognized again in two categories by the PEI Awards,” said Yann Robard, Managing Partner of Whitehorse. “For the fourth time among the top three Secondaries Firm of the Year in the Americas category (2018, 2020, 2022 and 2023) and the sixth time among the top three in the Firm of the Year in Canada category (2017, 2018, 2020, 2021, 2022 and 2023). You often hear us say that big is beautiful, growth is good and scale matters. Our scale has enabled us, not disrupted us. We
Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign1.3.2024 14:30:00 CET | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin KleinETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITYfragrance portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/ Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire) Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnerin
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV1.3.2024 13:35:00 CET | Press release
The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/ Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire) With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprie
GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta1.3.2024 09:37:00 CET | Press release
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom